In vivo three-dimensional brain imaging with chemiluminescence probes in Alzheimer's disease models.
In vivo three-dimensional brain imaging with chemiluminescence probes in Alzheimer's disease models.
复制标题
阿尔茨海默病模型中化学发光探针的体内三维脑成像。
DOI：
10.1073/pnas.2310131120
复制
发表时间：
2023-12
影响因子：
11.1
通讯作者：
Jing Zhang;C. Wickizer;Weihua Ding;Richard Van;Liuyue Yang;Biyue Zhu;Jun Yang;Yanli Wang;Yongle Wang;Yulong Xu;Can Zhang;Shiqian Shen;Changning Wang;Yihan Shao;Chongzhao Ran
中科院分区：
文献类型：
--
作者：
Jing Zhang;C. Wickizer;Weihua Ding;Richard Van;Liuyue Yang;Biyue Zhu;Jun Yang;Yanli Wang;Yongle Wang;Yulong Xu;Can Zhang;Shiqian Shen;Changning Wang;Yihan Shao;Chongzhao Ran
虽然磁共振成像（MRI）、正电子发射断层扫描（PET）、计算机断层扫描（CT）和单光子发射计算机断层扫描（SPECT）已常规用于3D（三维）成像，包括3D脑成像，但它们相当昂贵。光学成像在很大程度上是低成本和高吞吐量的。然而，光学成像的3D能力总是有限的。显然，光学3D分子成像是非常具有挑战性的，特别是对于3D脑成像。在本报告中，我们提供了一个使用化学发光探针ADLumin-Xs进行3D大脑成像的示例，该探针在量子产率（QY）、发射波长和信噪比（SNR）方面具有优势，可满足3D大脑成像的要求。我们相信，这种3D能力可能会改变临床前研究中大脑分子成像的游戏规则。
Significance Although magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and single-photon emission computerized tomography (SPECT) have been routinely used for 3D (three-dimensional) imaging, including 3D brain imaging, they are considerably expensive. Optical imaging is largely low-cost and high throughput. However, the 3D capacity of optical imaging is always limited. Obviously, optical 3D molecular imaging is highly challenging, particularly for 3D brain imaging. In this report, we provided an example of 3D brain imaging with chemiluminescence probes ADLumin-Xs, which have advantages in quantum yields (QY), emission wavelengths, and signal-to-noise ratios (SNRs) to fulfill the requirements for 3D brain imaging. And we believe that such 3D capacity is potentially a game changer for brain molecular imaging in preclinical studies.